Public Law 113–280
113th Congress

An Act

To reauthorize the United States Anti-Doping Agency, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “United States Anti-Doping Agency Reauthorization Act”.

SEC. 2. PROHIBIT PERFORMANCE-ENHANCING METHODS.


(1) in subsection (a), by striking paragraph (4); and
(2) in subsection (b)—
(A) in paragraph (1), by inserting “and be recognized worldwide as the independent national anti-doping organization for the United States” after “Committee”;
(B) in paragraph (2), by striking “, or performance-enhancing genetic modifications accomplished through gene-doping” and inserting “or prohibited performance-enhancing methods adopted by the Agency”;
(C) in paragraph (3), by striking “, or performance-enhancing genetic modifications accomplished through gene-doping” and inserting “or prohibited performance-enhancing methods adopted by the Agency”;
(D) in paragraph (4), by striking “and the prevention of use of performance-enhancing drugs, or performance-enhancing genetic modifications accomplished through gene-doping by United States amateur athletes; and” and inserting “, and the prevention of use by United States amateur athletes of performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency.”; and
(E) by striking paragraph (5).

SEC. 3. AUTHORIZATION OF APPROPRIATIONS.

Section 703 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows:

“SEC. 703. AUTHORIZATION OF APPROPRIATIONS.

“(1) for fiscal year 2014, $11,300,000;
“(2) for fiscal year 2015, $11,700,000;
“(3) for fiscal year 2016, $12,300,000;
“(4) for fiscal year 2017, $12,900,000;
“(5) for fiscal year 2018, $13,500,000;
“(6) for fiscal year 2019, $14,100,000; and
“(7) for fiscal year 2020, $14,800,000.”.

Approved December 18, 2014.